Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Venetoclax - AbbVie/Genentech

Drug Profile

Venetoclax - AbbVie/Genentech

Alternative Names: A-1195425.0; ABT 0199; ABT 199; GDC-0199; RG-7601; RO-5537382; Venclexta; VENCLYXTO

Latest Information Update: 04 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories; Genentech; Walter and Eliza Hall Institute of Medical Research
  • Developer AbbVie; Dana-Farber Cancer Institute; Emory University; Fondazione Italiana Linfomi; Gateway for Cancer Research; Genentech; Janssen Research & Development; Merck & Co; Nantes University Hospital; Nordic Lymphoma Group; Pharmacyclics; Roche; St. Jude Childrens Research Hospital
  • Class Antineoplastics; Benzamides; Heterocyclic bicyclo compounds; Piperazines; Pyrans; Pyridines; Pyrroles; Small molecules; Sulfonamides
  • Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia
  • Registered Acute myeloid leukaemia
  • Phase III Mantle-cell lymphoma
  • Phase II Breast cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; T-cell prolymphocytic leukaemia; Waldenstrom's macroglobulinaemia
  • Phase I/II Prostate cancer
  • Phase I Blastic plasmacytoid dendritic cell neoplasm; Cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Systemic lupus erythematosus
  • Discontinued Multiple myeloma

Most Recent Events

  • 29 Nov 2019 Registered for Chronic lymphocytic leukaemia in South Korea (PO) (NCT04178317)
  • 29 Nov 2019 Efficacy, pharmacokinetics and adverse events data from a phase I/II trial in Acute myeloid leukaemia presented at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-2019)
  • 21 Nov 2019 Efficacy, pharmacokinetics and adverse events data from a phase I trial in Acute myeloid leukaemia released by Abbvie
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top